As of 2025-11-05, the Intrinsic Value of Helix Biopharma Corp (HBP.TO) is -0.62 CAD. This HBP.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 2.00 CAD, the upside of Helix Biopharma Corp is -131.20%.
Based on its market price of 2.00 CAD and our intrinsic valuation, Helix Biopharma Corp (HBP.TO) is overvalued by 131.20%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -0.62 - -0.62 | -0.62 | -131.20% |
| P/E | (0.03) - (0.04) | (0.02) | -101.2% |
| DDM - Stable | (0.97) - (4.60) | (2.78) | -239.2% |
| DDM - Multi | (0.87) - (3.34) | (1.40) | -169.8% |
| Market Cap (mil) | 152.76 |
| Beta | 3.59 |
| Outstanding shares (mil) | 76.38 |
| Enterprise Value (mil) | 152.04 |
| Market risk premium | 5.10% |
| Cost of Equity | 9.73% |
| Cost of Debt | 5.00% |
| WACC | 6.71% |